Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Terry Lennie
共同編集者
Ohio State University

キーワード

概要

The purpose of is to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death.

説明

For a majority of patients with advanced heart failure, medical treatment is only partially effective in relieving heart failure symptoms. Therefore, it is recommended that palliative care be initiated soon after diagnosis. There is a need for complementary, nonpharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Clinical trials to date have only tested each nutrient individually. There is strong theoretical rationale that a combined intervention targeting all three nutrients would have substantial benefit in relieving symptoms in advanced heart failure. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this placebo controlled study are 1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; 2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and 3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 150 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group (75 per group). The nutrition intervention group will receive a theory based education and skill building intervention designed to decrease dietary sodium intake to ~2 g per day. A research nurse will make 4 home visits and one follow-up telephone call over 6 months to provide the education-skill building intervention. The intervention group will take 3 omega-3 fatty acid capsules (350 mg eicosapentaenoic acid and 50 mg docosahexaenoic acid) and consume tomato juice or other tomato-based products containing 20-25 mg of lycopene daily for six months. The placebo group will receive the same number of visits and phone calls but only general nutrition information will be provided. They will take 3 placebo capsules containing rice oil (500 mg/capsule) and consume their choice of fruit juices that do not contain lycopene daily for six months. Data will be collected in person at baseline, 3 months, and 6 months by a research assistant blinded to the group assignment. Patients will be followed for an additional 6 months by telephone to collect longer term data on symptom burden and quality of life as well as heart failure hospitalization and all-cause mortality at 9 and 12 months.

日付

最終確認済み: 02/28/2017
最初に提出された: 11/14/2012
提出された推定登録数: 11/18/2012
最初の投稿: 11/25/2012
最終更新が送信されました: 03/14/2017
最終更新日: 03/16/2017
実際の研究開始日: 10/31/2011
一次完了予定日: 12/31/2016
研究完了予定日: 12/31/2016

状態または病気

Heart Failure

介入/治療

Behavioral: sodium reduction, omega-3, lycopene

Dietary Supplement: sodium reduction, omega-3, lycopene

Dietary Supplement: Control

Behavioral: Control

段階

段階 2

アームグループ

介入/治療
Experimental: sodium reduction, omega-3, lycopene
combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
Behavioral: sodium reduction, omega-3, lycopene
Teaching and skill building to reduce dietary sodium
Placebo Comparator: Control
Limited nutritional counseling, juice without lycopene, rice oil capsules
Dietary Supplement: Control
placebo capsules

適格基準

研究の対象となる年齢 21 Years に 21 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- chronic heart failure with either preserved or non-preserved ejection fraction

- for chronic heart failure, have undergone evaluation of heart failure and optimization of medical therapy, for patients discharged from hospital for acute/newly diagnosed heart failure, have undergone evaluation of heart failure and optimization of medical therapy for at least 1 month post discharge

- New York Heart Association functional classification of II, III or IV

- have not been referred for heart transplantation

- able to read and speak English

- no cognitive impairment that precludes giving informed consent or ability to follow protocol instruction.

Exclusion Criteria:

- BMI < 17 kg/m2 or > 46 kg/m2

- co-existing illness documented in the medical record known to be associated with systemic inflammation decreased appetite or absorption, fatigue, edema, or weight loss

- currently taking dietary supplements that contain lycopene or omega-3 fatty acids

- allergy to rice bran oil

結果

主な結果の測定

1. Event-Free Survival [12 months]

Combined endpoint of cardiac-related hospitalization and all cause mortality

2. Symptom burden [baseline, 3, 6, 9, and 12 months]

combined score of symptom severity, frequency, and distress for common symptoms of heart failure

3. Quality of life [baseline, 3, 6, 9, 12 months]

heart failure related quality of life

二次的な結果の測定

1. omega-3 index [baseline, 3, 6, 9, 12 months]

the ratio of EPA plus DHA as a percentage of total fatty acids in the cell membrane of erythrocytes

2. oxidative stress [baseline, 3, 6, 9, 12 months]

serum levels of malondialdehyde and 8-iso-PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen free radical production exceeding antioxidant capacity

3. Inflammation [baseline, 3, 6, 9, 12 months]

Serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors: sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity; interleukin-10 (IL-10) will be measured as a marker of anti-inflammatory cytokine activity

4. Lycopene [baseline, 3, 6, 9, 12 months]

Plasma lycopene will be measured as a marker intervention effectiveness

5. Sodium intake [baseline, 3, 6, 9, 12 months]

Three 24-hour diet recall interviews at each timepoint will be used estimate sodium intake and to identify high sodium foods and eating patterns for the sodium reduction component of the intervention.

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge